A bill aiming to make opioid treatment programs unlawful was introduced into the West Virginia Senate last week.
Senate Bill 204, which says an “Opioid treatment program” means a program or practitioner engaged in the treatment of ...
The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.
A recent study suggests that the dopamine D3 receptor partial agonist BP 897 prevents cocaine-seeking behavior in rats, and this may lead to new approaches to study and treat drug addiction.
1d
Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...
Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms.
Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback